Wakui, Masatoshi

写真a

Affiliation

School of Medicine, Department of Laboratory Medicine (Shinanomachi)

Position

Associate Professor

External Links

Other Affiliation 【 Display / hide

  • (兼務所属)慶應義塾大学病院臨床研究推進センター, 再生医療等支援部門, センター員

Career 【 Display / hide

  • 1989
    -
    1991

    慶應義塾大学医学部研修医(内科)

  • 1991
    -
    1993

    慶應義塾大学医学部助手(専修医)(内科学)

  • 1991
    -
    1993

    横浜市立市民病院内科

  • 1993
    -
    1995

    慶應義塾大学医学部内科学教室血液研究室(専修医)

  • 1995
    -
    1997

    慶應義塾大学助手(医学部内科学)

display all >>

Academic Background 【 Display / hide

  • 1983.04
    -
    1989.03

    Keio University, School of Medicine, 医学科

    Japan, University, Graduated

Academic Degrees 【 Display / hide

  • 博士(医学), Keio University, Dissertation, 2006.09

    Genetic dissection of systemic lupus erythematosus pathogenesis : partial functional complementation between Sle1 and Sle3/5 demonstrates requirement for intracellular coexpression for full phenotypic expression of lupus(全身性エリテマトーデスの成因に関する遺伝学的解析 : Sle1とSle3/5の部分的機能補完は、完全なループス表現型発現のために細胞内共発現が要求されることを示す)

Licenses and Qualifications 【 Display / hide

  • 臨床研修指導医, 第16回慶應義塾大学病院臨床研修指導医養成WS受講

  • 医師免許, 1989.05

  • 臨床検査専門医, 2017.09

  • 臨床検査管理医, 2017.12

  • 日本血栓止血学会認定医, 2020

 

Research Areas 【 Display / hide

  • Tumor biology

  • Tumor diagnostics

  • Medical genome science

  • Pathological medical chemistry

  • Immunology

display all >>

 

Books 【 Display / hide

  • スタンダード検査血液学(第4版)

    日本検査血液学会編, 医歯薬出版株式会社, 2021.04

  • 検査値の読み方・考え方〜専門医からのアドバイス(第3版)

    WAKUI Masatoshi, 総合医学社, 2021

  • 臨床検査ガイド2020〜2021

    2019,  Page: 印刷中

  • 看護に役立つ検査値の読み方・考え方

    WAKUI Masatoshi, 総合医学社, 2015

  • 臨床検査ガイド2015〜2016

    WAKUI Masatoshi, 文光堂, 2015

display all >>

Papers 【 Display / hide

  • Characterization of antithrombin-dependent anticoagulants through clot waveform analysis to potentially distinguish them from antithrombin-independent inhibitors targeting activated coagulation factors

    Wakui M, Fujimori Y, Nakamura S, Oka S, Ozaki Y, Kondo Y, Nakagawa T, Katagiri H, Murata M

    Journal of Clinical Pathology (Journal of Clinical Pathology)  74 ( 4 ) 251 - 256 2021

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  00219746

     View Summary

    © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. Aims: While antithrombin (AT)-independent inhibitors targeting thrombin or activated factor X have been assessed through clot waveform (CWA), there are no reports on assessment with respect to AT-dependent anticoagulants. The present study aims to characterise AT-dependent anticoagulants through CWA to distinguish them from AT-independent inhibitors. Methods: CWA was applied to the activated partial thromboplastin time (APTT) assay of plasma samples spiked with each of AT-dependent drugs (unfractionated heparin, enoxaparin and fondaparinux) and AT-independent drugs (rivaroxaban, apixaban, edoxaban, dabigatran, argatroban, hirudin and bivalirudin), which was performed using the CS-5100 or CN-6000 (Sysmex). The APTT-CWA data were automatically gained by the analyser program. The positive mode of clotting reaction curves was defined as the direction towards fibrin generation. Results: Regarding dose-response curves in AT-dependent anticoagulants, the maximum positive values of the first and secondary derivatives (Max1 and Maxp2, respectively) and the maximum negative values of the secondary derivative (Maxn2) seemed to drop to zero without making an asymptotic line, consistent with the irreversibility. Such a feature was observed also in hirudin, as reported previously. Notably, the symmetric property of Max1 peaks in the waveforms was distorted dose dependently in AT independent but not AT-dependent drugs. A plot of Maxp2 logarithm versus Maxn2 logarithm was linear. The slope was about 1 in AT-dependent drugs while that was more than 1 in AT-independent drugs. These features made it possible to distinguish AT-dependent and AT-independent drugs. Conclusions: The results aid in further understanding of the pharmacological aspects of anticoagulation and in screening of candidates for novel anticoagulants.

  • Evaluation of usability of various rapid antibody tests in diagnostic application for COVID-19

    Uwamino Y, Wakui M*#, Aoki W, Kurafuji T, Yanagita E, Morita M, Nagata M, nose R, Noguchi M, Yokota H, Hasegawa N, Saya H, Murata M and for the Keio Donner Project Team

    Annal Clin Biochem ({SAGE} Publications)  58 ( 3 ) 174 - 180 2021

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  00045632

     View Summary

    © The Author(s) 2021. Background: The usability of laboratory tests related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critically important for the world undergoing the COVID-19 pandemic. The present study aimed to assess the diagnostic usability of rapid tests for the detection of antibody against SARS-CoV-2 through comparison of their results with the results of reverse transcription polymerase chain reaction (RT-PCR) test for the detection of SARS-CoV-2 genomic RNA and with the results of a quantitative test for antibody detection. Methods: Serum samples were collected from 18 patients undergoing RT-PCR testing for SARS-CoV-2. Twelve patients were RT-PCR positive while six were negative. A quantitative test based on chemiluminescent immunoassay and three rapid tests based on immunochromatography were performed to detect anti-SARS-CoV-2 IgG and IgM. Results: All the antibody tests exhibited poor sensitivity at the timing of initial RT-PCR diagnosis. IgG responses occurring prior to or simultaneously with IgM responses were observed through not only the quantitative test but also the three rapid tests. Based on concordance with the quantitative test results, the large variance among the three rapid tests was revealed. Conclusions: All antibody tests were unsatisfactory to replace RT-PCR for the early diagnosis of COVID-19. Rapid antibody tests as well as a quantitative antibody test were useful in the assessment of immune responses in COVID-19. The obvious variance among the three rapid tests suggested limited accuracy and difficult standardization. Diagnostic usability of rapid antibody tests for COVID-19 should be investigated rigorously.

  • How clinical laboratory physicians should stand and go on in near future: Their individuality and cooperativity expected for medical practice and science— Chairpersons’ remarks —

    Wakui M, Tabe Y

    Rinsho Byori (日本臨床検査医学会)  印刷中 2021

    Research paper (scientific journal), Except for reviews

  • Assessment of humoral responses in COVID-19 using various quantitative antibody tests

    Wakui M, Uwamino Y, Kurafuji T, Noguchi M, Ohno A, Yokota H, Kikuchi H, Hasegawa N, Saya H, Murata M and for the Keio Donner Project Team

    Ann Clin Biochem ({SAGE} Publications)  58 ( 4 ) 368 - 376 2021

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  00045632

     View Summary

    Background: Quantitative antibody tests are expected to be useful in diagnostics of COVID-19 and investigation of herd immunity against SARS-CoV-2. To make it proper to perform them, understanding of the immunological aspects is critically important. The present study aimed to assess humoral responses in COVID-19 using various quantitative antibody tests. Methods: Four quantitative antibody tests that are different in targeted antigens, detectable immunoglobulin classes and avidity were used. Diagnosis was confirmed by RT-PCR for SARS-CoV-2 detection. Antibody titres of 117 samples collected from 24 COVID-19 patients and 23 non-COVID-19 patients were measured to evaluate correlations between different tests. For 24 COVID-19 patients, antibody titres measured at various time points after the onset or the RT-PCR diagnosis were subjected to assessment of humoral responses. Results: Correlations between tests were observed to some degree, although there were discrepancies putatively due to differences in measurement principle. Seronegative COVID-19 was diagnosed for some patients, in whom antibody titres were less than the cut-off value in each test throughout the time courses. IgG seroconversion without prior IgM seroconversion most frequently occurred, while predominance of IgM responses over IgG responses was observed in some severe cases. Viral burdens estimated according to threshold cycle values at the RT-PCR seemed to impact antibody responses. Conclusions: The results provide insights into the nature of humoral responses to SARS-CoV-2 and diagnostic performance of antibody tests.

  • Alinity hq platelet results are equivalent with the international reference method in thrombocytopenic samples

    Lifson MA, Wakui M, Arai T, Mitsuhashi T, Lakos G, Murata M

    Int J Lab Hematol (International Journal of Laboratory Hematology)  in press 2021

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  17515521

     View Summary

    Introduction: Accurate and precise platelet (PLT) count is critical for the appropriate management of patients with thrombocytopenia. This study evaluated the performance of PLT counting with the Abbott Alinity hq hematology analyzer, which utilizes multi-dimensional optical technology. Methods: Imprecision, linearity, and accuracy were assessed per CLSI guidelines. Alinity hq PLT results were compared to the international flow cytometry reference method (IRM) in the concentration range of 6.3 to 103.0 × 109/L. Additional comparisons were made with Sysmex XN-3000 PLT counts: impedance (PLT-I), optical (PLT-O), and optical fluorescent (PLT-F) methods. Results: The average within-run %CV was 4.7% on patient samples with PLT concentrations ranging from 13.1 to 41.7 × 109/L, and the within-laboratory %CV was 3.6% at the level of 68.2 × 109/L. Linearity evaluation indicated a maximum deviation of 3.1% from the linear fit in the range of 0.1 to 316.8 × 109/L. Comparison between Alinity hq and the IRM PLT counts yielded a correlation coefficient of 0.99 and predicted bias of 0.0 and −0.5 × 109/L at 10.0 and 20.0 × 109/L transfusion thresholds, respectively. Alinity hq PLT counts also correlated well with Sysmex PLT counts, with strongest correlation obtained with PLT-F and PLT-O (r =.99) methods. Conclusion: This study demonstrated excellent analytical performance of Alinity hq PLT counting in thrombocytopenic samples, equivalency with the IRM and strong agreement with Sysmex PLT-F and PLT-O methods. The Alinity hq multi-dimensional optical PLT count is available with every CBC without additional reagents and may help promote efficiency in clinical laboratories.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • 出血性素因

    涌井 昌俊

    臨床検査 (医学書院)  印刷中 2019

    Introduction and explanation (commerce magazine), Single Work

  • 静脈血栓症と臨床検査

    藤森祐多、涌井昌俊、村田満

    カレントテラピー (ライフメディコム社)  印刷中 2019

    Introduction and explanation (commerce magazine), Joint Work

  • いま問われる「学問の独立」:大学を取りまく社会と学問(座談会)

    WAKUI Masatoshi

    三田評論 (慶應義塾大学出版会)   ( 1195 ) 10 - 24 2015.12

    Other article, Joint Work

Presentations 【 Display / hide

  • 凝固線溶波形解析に基づく凝固第XIII因子が線溶に与える影響に関する検討

    岡周作、涌井昌俊、藤森祐多、尾﨑裕子、中村祥子、近藤佳乃、中川央充、片桐尚子、村田満

    第68回日本臨床検査医学会学術集会 (富山) , 2021.11, Oral Presentation(general), 日本臨床検査医学会

  • COVID-19陽性血清を用いたAlinity SARS-CoV-2 IgG Ⅱ Quantの性能評価とワクチン接種後の抗体獲得状況の調査

    藏藤利暢、上蓑義典、野口昌代、大野明美、横田浩充、涌井昌俊、村田満

    第68回日本臨床検査医学会学術集会 (富山) , 2021.11, Oral Presentation(general), 日本臨床検査医学会

  • Significance of antibody testing for vaccinated people

    Masatoshi Wakui, M.D., Ph.D.

    The 8th NIKKEI FT Communicable Diseases Conference (Tokyo) , 2021.10, Public discourse, seminar, tutorial, course, lecture and others, Nikkei, Inc.

  • 全自動総合血液学分析装置Alinity hqの低値域における血小板数の信頼性の検証

    荒木美香、谷田部陽子、矢作かおり、片桐尚子、荒井智子、横田浩充、中山洋一、三ツ橋雄之、涌井昌俊、村田満

    第22回日本検査血液学会学術集会 (秦野) , 2021.09, Oral Presentation(general), 日本検査血液学会

  • 全自動血球計数器Celltac G+の基礎的性能評価(I)

    森勇人、谷田部陽子、片桐尚子、近藤直美、荒木美香、荒井智子、永井豊、涌井昌俊、三ツ橋雄之、村田満

    第22回日本検査血液学会学術集会 (秦野) , 2021.09, Oral Presentation(general), 日本検査血液学会

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 日本の医療従事者におけるCOVID-19ワクチンの液性・細胞性免疫応答と副反応の研究

    2021
    -
    Present

    公益財団法人予防接種リサーチセンター, 公益財団法人予防接種リサーチセンター研究費事業, 上蓑義典(研究代表者), 涌井昌俊(研究分担者), No Setting, Co-investigator

  • Exploration into the nature of direct oral anticoagulants (DOACs) from the perspective of laboratory hematology and its application to the management of bleeding risk on medication

    2017.04
    -
    2019.03

    (株)ブリストル・マイヤーズ スクイブ/(株)ファイザー, JRISTA, Masatoshi Wakui, M.D., Ph.D., Principal Investigator

  • 悪性胸膜中皮腫に対するゾレドロン酸によるオートファジー誘導薬物療法

    2014.04
    -
    2017.03

    独立行政法人日本学術振興会, Grant-in-Aid for Scientific Research, 朝倉啓介, No Setting, Co-investigator

  • 遺伝子発現エントロピー解析による腫瘍不均一性の検証

    2013.04
    -
    2016.03

    Grant-in-Aid for Scientific Research, 涌井昌俊, No Setting, Principal Investigator

  • イメージングマススペクトロメトリーのための統計解析法の開発

    2012.04
    -
    2015.03

    Grant-in-Aid for Scientific Research, 公益財団法人 がん研究会・松浦正明, No Setting, Co-investigator

display all >>

Intellectual Property Rights, etc. 【 Display / hide

  • 質量分析データ処理方法及び装置(分割出願)

    Application No.: 特願2016-074892  2016.04 

    Announcement No.: 特開2016-153798  2016.08 

    Registration No.: 特許第6207036号  2017.09

    Patent, Joint, National application

  • MASS-ANALYSYS DATA PROCESSING METHOD AND SYSTEM

    Application No.: US. Patent Application NO.13/458,850  2012.04 

    Announcement No.: US. Patent Application Publication NO.US2012/0278037 A1  2012.11 

    Registration No.: 特許番号10012572  2018.07

    Patent, Joint, PCT international application

  • 質量分析データ処理方法及び装置

    Application No.: 特願2012-102636  2012.04 

    Announcement No.: 特開2012-237753  2012.12 

    Registration No.: 特許第6025141号  2016.10

    Patent, Joint, National application

  • 免疫応答修飾活性の試験管内評価方法

    Application No.: JP2005019149  2005.10 

    Announcement No.: WO2006-054415  2006.05 

    Registration No.: 4886521  2011.12

    Patent, Joint

  • 移植片対宿主病の早期診断用オリゴヌクレオチド塩基配列

    Application No.: 特願2000-324400  2000.10 

    Announcement No.: 特開2002-125679  2002.05 

    Patent, Joint, National application

display all >>

Other 【 Display / hide

  • peer-review

     View Details

    peer-review (International Journal of Hematology)

  • peer review

     View Details

    peer review (Inflammation and Regeneration)

  • peer-review

     View Details

    peer-review (Clinical and Applied Thrombosis/Hemostasis)

  • peer-review

     View Details

    peer-review (Diagnostic Microbiology and Infectious Disease)

  • peer-review

     View Details

    peer-review (International Journal of Laboratory Hematology)

display all >>

 

Courses Taught 【 Display / hide

  • LECTURE SERIES, LABORATORY MEDICINE

    2021

  • ADVANCED MEDICAL TECHNOLOGIES

    2021

  • ADVANCED MEDICAL TECHNOLOGIES

    2020

  • 生化学講義(早稲田大学 先進理工学部)

    2020, Lecture

  • 臨床検査学臨床実習(医学部)

    2020, Laboratory work/practical work/exercise

display all >>

Courses Previously Taught 【 Display / hide

  • 臨床検査学

    Keio University, 2018, Full academic year, Laboratory work/practical work/exercise

  • 臨床検査学

    Keio University, 2018, Autumn Semester, Seminar

  • 実験動物医学

    Keio University, 2018, Spring Semester, Lecture

  • 基礎腫瘍学

    Keio University, 2018, Spring Semester, Major subject, Lecture

  • 臨床検査学

    Keio University, 2018, Spring Semester, Major subject, Lecture, Within own faculty

display all >>

Educational Activities and Special Notes 【 Display / hide

  • OSCE内部評価者

    2020
    -
    Present

    , Special Affairs

  • 医療系三学部合同教育

    2018
    -
    Present

    , Special Affairs

  • 病院での臨床検査. 第1版, 東京:慶應義塾大学薬学部

    2013

    , Development of Textbook and Teaching Material

  • 医学部カリキュラム委員会

    2010
    -
    2014

    , Special Affairs

  • 医学部入試試験監督

    2010

    , Special Affairs

display all >>

 

Social Activities 【 Display / hide

  • APAC Customer Focus Group Session

    Roche Diagnostics International Ltd,  (Online)

    2021.07
  • 日本臨床検査専門学院第46期(令和3年度)血液学コースカリキュラム

    一般社団法人 日本衛生検査所協会

    2021
    -
    Present
  • 『臨床検査』誌編集委員

    医学書院

    2019.11
    -
    Present
  • 2019年度慶應連合三田会大会実行委員(救護部会)

    2019年度慶應連合三田会大会実行委員会, 2019年度慶應連合三田会大会 (慶應義塾大学 日吉キャンパス)

    2019.10
  • 『臨床検査』誌ゲストエディター

    医学書院, 臨床検査, 

    2019
    -
    Present

display all >>

Memberships in Academic Societies 【 Display / hide

  • 日本臨床化学会, 

    2019.01
    -
    Present
  • 日本臨床検査専門医会, 

    2018.01
    -
    Present
  • 日本医用マススペクトル学会, 

    2018
    -
    Present
  • International Society of Laboratory Hematology, 

    2016
    -
    Present
  • 慶應医学会, 

    1989
    -
    Present

display all >>

Committee Experiences 【 Display / hide

  • 2021.11

    日本検査血液学会共催シンポジウム座長 , 第68回日本臨床検査医学会学術集会(富山)

  • 2021.11

    日本臨床検査専門医会共催シンポジウム座長, 第68回日本臨床検査医学会学術集会(富山)

  • 2021.06

    特別講演「凝固障害症の検査における凝固波形解析の発展〜血友病医療の止血モニタリングへの応用〜」座長, 第10回血栓止血検査研究会-Tokyo

  • 2021.05

    一般演題(口演)座長 , 第43回日本血栓止血学会学術集会(宮崎)

  • 2021.04
    -
    Present

    日本血栓止血学会編集委員会, 日本血栓止血学会

display all >>